Skip to main content

Table 1 Differential human gene expression in 3D prostate cancer/preosteoblast heterotypical organoids treated with hormone agonists and anti-AR treatment

From: Androgen receptor variant-7 regulation by tenascin-c induced src activation

22Rv1 Upregulated

22Rv1 Downregulated

MousePre-osteoblast

Testosterone1nM

Estradiol10nM

Enzalutamide10µM

MousePre-osteoblast

Testosterone1nM

Estradiol10nM

Enzalutamide10µM

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

BMP2

9.86E-05

ELF3

1.98E-04

BMP2

1.11E-03

BMP2

1.50E-03

ICAM1

5.50E-03

BMP2

6.91E-06

ICAM1

2.27E-05

BMP6

4.02E-03

IHH

4.90E-02

TGFβ1

2.96E-02

IHH

1.90E-02

IHH

5.38E-03

FGF9

2.77E-02

BMP6

1.30E-02

FGF9

2.00E-02

GlI1

4.44E-04

SOX9

3.90E-02

SOX9

6.36E-04

SHH

1.14E-02

ELF3

2.96E-05

  

IHH

4.50E-02

IL1α

5.62E-04

GlI2

3.34E-04

PTCH1

2.17E-03

ITGβ1

2.00E-02

SOX9

7.13E-04

PTCH1

9.14E-04

  

PTCH1

7.61E-03

CSF3

7.60E-03

ICAM1

9.74E-03

TGFβ1

4.68E-04

  

GlI1

1.30E-03

Gli3

1.64E-02

  

GlI1

2.88E-04

ESR1

9.85E-04

FGF9

4.70E-04

ELF3

2.64E-03

  

GlI3

7.50E-03

TGFβ1

3.55E-03

  

GlI2

1.74E-02

ESR2

4.48E-03

IL1α

5.04E-06

ITGβ1

1.08E-03

  

TGFβ1

2.29E-02

ITGβ1

2.34E-03

  

GlI3

2.08E-03

MMP16

1.51E-03

CSF3

9.07E-03

PTK2

1.40E-02

  

ELF3

3.16E-05

ESR1

7.72E-05

  

ICAM1

2.13E-03

  

ESR2

5.90E-04

    

ITGβ1

5.00E-03

    

FGF9

1.70E-02

  

MMP16

2.49E-03

          

IL1α

4.71E-03

    
          

CSF3

6.27E-03

    
          

ESR2

2.46E-03

    
          

MMP16

1.15E-03

    

VCaP Upregulated

VCaP Downregulated

MousePre-osteoblast

Testosterone1nM

Estradiol10nM

Enzalutamide10µM

MousePre-osteoblast

Testosterone1nM

Estradiol10nM

Enzalutamide10µM

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

Genes

P-value

BMP2

2.36E-03

SOX9

9.26E-06

BMP2

7.40E-05

BMP7

2.07E-02

ICAM1

2.32E-03

BMP2

4.29E-03

ICAM1

7.06E-03

BMP6

3.48E-05

BMP6

1.54E-03

IGF1

6.05E-05

BMP6

3.56E-02

SHH

2.13E-03

FGF9

1.83E-05

BMP6

2.28E-02

FGF9

6.10E-03

IHH

4.17E-04

IHH

3.87E-03

  

BMP7

2.73E-03

SOX9

4.39E-04

MMP16

2.40E-04

BMP7

2.34E-02

MMP16

1.82E-04

GlI1

9.31E-05

SHH

3.44E-03

  

IHH

4.27E-04

PTCH1

9.15E-03

  

IHH

6.40E-03

  

ICAM1

9.74E-06

SOX9

9.91E-04

  

SHH

3.80E-02

GlI2

1.36E-03

  

SHH

5.20E-03

  

FGF9

4.97E-04

PTCH1

2.64E-02

  

SOX9

1.63E-05

IGF1

1.75E-02

  

PTCH1

6.53E-03

  

IL1α

1.11E-03

    

GlI1

9.62E-03

TGFβ1

2.23E-02

  

GlI1

2.34E-04

  

MMP16

3.03E-05

    

GlI2

8.63E-03

ITGβ1

3.52E-02

  

GlI2

3.99E-04

    
    

GlI3

1.01E-02

    

ICAM1

5.63E-03

    
    

IGF1

1.81E-05

    

FGF9

2.71E-03

    
          

IL1α

1.29E-04

    
          

MMP16

1.25E-03

    
  1. Gene expression analysis was conducted using RT-qPCR. Statistical significance was ascertained by comparing the relative mRNA expression in 3D heterotypical organoids (treated with hormone agonist and anti-AR treatment) versus corresponding 3D cancer monocultures. Human specific primers used in the assay are summarized in Additional file 1: Table S1. Data represent mean ± SD, n = 3, *p < 0.05; ** p < 0.01; ***p < 0.001; ****p < 0.0001
Back to article page

Cell Communication and Signaling

ISSN: 1478-811X